Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-SF3B1 Antibody (R1F47)

Catalog #:   RHB24001 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IF, IHC, WB
Accession: O75533
Overview

Catalog No.

RHB24001

Species reactivity

Human, Mouse, Rat, Hamster

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:50-1:100, WB: 1:500-1:1000

Target

SAP 155, SAP155, SF3B1, Pre-mRNA-splicing factor SF3b 155 kDa subunit, Splicing factor 3B subunit 1, Spliceosome-associated protein 155, SF3b155

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O75533

Applications

IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1F47

Data Image
  • Immunofluorescence
    Immunocytochemistry analysis of SF3B1 (green) in 293T using SF3B1 antibody,and DAPI(blue).
  • Immunohistochemical
    Immunohistochemistry analysis of paraffin-embedded Human lung cancer using SF3B1 antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.
  • Western blot
    Western blot analysis of SF3B1 in 3T3 lysates using SF3B1 antibody.
  • Western blot
    Western blot analysis of SF3B1 in Hela, CHO-K1, C6, Ramos lysates using SF3B1 antibody
References

Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China., PMID:40474348

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes., PMID:40334184

Association of Specific Gene Mutations with Immunoglobulin Heavy-Chain Variable Region and Chromosomal Alterations in Chronic Lymphocytic Leukemia Patients in India., PMID:39873992

Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept., PMID:39644054

Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis., PMID:39251642

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)., PMID:38654616

Chronic Lymphocytic Leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing., PMID:38175592

Targeting transforming growth factor beta signaling in metastatic osteosarcoma., PMID:38021074

Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer., PMID:38012150

Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review., PMID:37551557

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia., PMID:37511096

Activation of distinct inflammatory pathways in subgroups of LR-MDS., PMID:37420006

[Clinical analysis of 20 cases of small B lymphocyte proliferative disease with t (14;19) (q32;q13)]., PMID:36709153

STEREOTYPED CASES IN UKRAINIAN COHORT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DEPENDING ON THE IONIZING RADIATION EXPOSURE., PMID:36582097

Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience., PMID:35392224

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)., PMID:34506616

The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients., PMID:34492598

[Chronic lymphocytic leukemia with t (14;18) (q32;q21) : report of eight cases and a literature review]., PMID:34455745

Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3., PMID:34442029

Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation., PMID:34265801

The protein landscape of chronic lymphocytic leukemia., PMID:34189564

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma., PMID:33922591

Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2., PMID:33801781

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients., PMID:33730841

Development of luspatercept to treat ineffective erythropoiesis., PMID:33687432

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes., PMID:33539200

IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics., PMID:33211804

Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications., PMID:32720348

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax., PMID:32206772

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes., PMID:32179032

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial., PMID:32015491

98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia., PMID:31849198

Pathophysiology of chronic lymphocytic leukemia and human B1 cell development., PMID:31797231

Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia., PMID:31230372

Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience., PMID:31054420

Analysis of LPL gene expression in patients with chronic lymphocytic leukemia., PMID:30932419

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab., PMID:30842083

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion., PMID:30712845

Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment., PMID:30686074

THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT., PMID:30582853

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group., PMID:30203893

Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses., PMID:30022491

Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma., PMID:29954402

Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers., PMID:29796163

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients., PMID:29745034

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation., PMID:29367434

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients., PMID:29365086

Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia., PMID:28994094

Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL., PMID:28925785

A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors., PMID:28892161

Datasheet

Document Download

Anti-SF3B1 Antibody (R1F47).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-SF3B1 Antibody (R1F47) [RHB24001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only